{"id":"NCT02606461","sponsor":"Karyopharm Therapeutics Inc","briefTitle":"Selinexor in Advanced Liposarcoma","officialTitle":"A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2016-01-04","primaryCompletion":"2020-10-28","completion":"2021-10-26","firstPosted":"2015-11-17","resultsPosted":"2021-12-07","lastUpdate":"2023-01-23"},"enrollment":342,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Dedifferentiated Liposarcoma"],"interventions":[{"type":"DRUG","name":"Selinexor","otherNames":["KPT-330"]},{"type":"DRUG","name":"Placebo","otherNames":["sugar pill"]}],"arms":[{"label":"Phase 2 Double-blinded: Selinexor","type":"EXPERIMENTAL"},{"label":"Phase 3 Double-blinded: Selinexor","type":"EXPERIMENTAL"},{"label":"Phase 2 Double-blinded: Placebo Followed by Open Label- Selinexor","type":"PLACEBO_COMPARATOR"},{"label":"Phase 3 Double-blinded: Placebo Followed by Open Label- Selinexor","type":"PLACEBO_COMPARATOR"}],"summary":"This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).","primaryOutcome":{"measure":"Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1","timeFrame":"From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)","effectByArm":[{"arm":"Phase 3 Double-blinded: Selinexor","deltaMin":2.83,"sd":null},{"arm":"Phase 3 Double-blinded: Placebo","deltaMin":2.07,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0114"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":71,"countries":["United States","Belgium","Canada","France","Germany","Israel","Italy","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["35394800"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":27},"commonTop":["Nausea","Decreased appetite","Fatigue","Anaemia","Vomiting"]}}